Breast Cancer

Triple Negative Breast Cancer

Female, 38 years

Patient Internal ID: 103601730

ICD-10 code

C50.5 Malignant Neoplasm of Lower-Outer Quadrant of Breast

Diagnosis (Incl. Metastases/Stage) and Year

July 2014 – Left Breast Carcinoma pT1aN1a G3 ER-, PR-, HER2-, Stage IIa (2014). Right Breast Carcinoma pT1cN0 G3 ER-, PR-, HER2-, Stage IA (2015). Disease recurrence rT4bNx G3 ER-, PR-, HER2- in March 2018.
Disease progression in June 2019 – Metastasis in the Lungs, in 2020 – Multiple Brain Metastases.

Previous Treatment

Surgery, Chemotherapy (Paclitaxel), Radiation Therapy, Surgery, Chemotherapy (Docetaxel), Radiation Therapy, Chemotherapy (Capecitabine), Surgery (Both Breast Mastectomy), Chemotherapy (Docetaxel and Carboplatin), Chemotherapy (Docetaxel and Cyclophosphamide), Chemotherapy (Eribulin), Radiation Therapy (Gama Knife), Chemotherapy (Eribulin), Chemotherapy (Vinorelbine).

Prognosis and Survival Expectation

The prognosis remains poor, the median overall survival for patients with Metastatic Triple Negative Breast Cancer is about 9–12 months.

Treatment Provided

Autologous DCV (5 doses) and CIK (4 doses) over a period of 15 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (13 doses), Immunostimulation of Interferon (IFN) β and Tumor Necrosis Factor (TNF), as well as Mistletoe Therapy.

Patient Survival/Condition and Year
Date of Review: 06/12/2023

The patient has survived for 45 months. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy and Radiation Therapy, has extended patient survival by an estimate of around 33 months.